- Home
- CB vs GNLX Comparison
CB vs GNLX Comparison
Compare CB & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CB
- GNLX
- Stock Information
- Founded
- CB 1985
- GNLX 2001
- Country
- CB Switzerland
- GNLX United States
- Employees
- CB N/A
- GNLX N/A
- Industry
- CB Property-Casualty Insurers
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- CB Finance
- GNLX Health Care
- Exchange
- CB Nasdaq
- GNLX Nasdaq
- Market Cap
- CB 117.0B
- GNLX 112.5M
- IPO Year
- CB 1993
- GNLX 2023
- Fundamental
- Price
- CB $278.00
- GNLX $3.44
- Analyst Decision
- CB Buy
- GNLX Strong Buy
- Analyst Count
- CB 14
- GNLX 4
- Target Price
- CB $307.57
- GNLX $17.75
- AVG Volume (30 Days)
- CB 1.6M
- GNLX 152.2K
- Earning Date
- CB 07-22-2025
- GNLX 08-13-2025
- Dividend Yield
- CB 1.40%
- GNLX N/A
- EPS Growth
- CB N/A
- GNLX N/A
- EPS
- CB 20.78
- GNLX N/A
- Revenue
- CB $56,307,000,000.00
- GNLX N/A
- Revenue This Year
- CB N/A
- GNLX N/A
- Revenue Next Year
- CB $6.03
- GNLX N/A
- P/E Ratio
- CB $13.38
- GNLX N/A
- Revenue Growth
- CB 8.74
- GNLX N/A
- 52 Week Low
- CB $252.16
- GNLX $1.60
- 52 Week High
- CB $306.91
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- CB 39.75
- GNLX 65.71
- Support Level
- CB $277.45
- GNLX $2.80
- Resistance Level
- CB $281.27
- GNLX $3.61
- Average True Range (ATR)
- CB 4.76
- GNLX 0.22
- MACD
- CB -0.61
- GNLX 0.05
- Stochastic Oscillator
- CB 6.50
- GNLX 80.23
About CB Chubb Limited
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination made the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.